Learn how to create burndown charts to track project progress, improve team performance, and download free templates to get ...

Nektar Therapeutics just saw its fair value model refreshed, with the headline number holding steady at US$114.43 per share even as the long term revenue growth assumption for Rezpeg edged to a 10.83% ...

Lumen Technologies, Inc.’s turnaround continues: revenue still declining, but AI deals lift deferred revenue. Click for this LUMN stock update.

Now this season, Barkley's stats in wins and losses don't differ all that much.

The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 ...